publication . Article . 2015

Papel de los bisfosfonatos en la osteonecrosis mandibular

J.R. Aguilera Pérez; J. Hernández Reyna;
Open Access English
  • Published: 01 Jan 2015 Journal: Perinatología y Reproducción Humana (issn: 0187-5337, Copyright policy)
  • Publisher: Permanyer
Abstract
ResumenLos bisfosfonatos son fármacos utilizados en el manejo de los trastornos primarios y secundarios del hueso, principalmente en la osteoporosis, tanto local como general, enfermedades metabólicas óseas, calcificación de tejidos blandos y estados de hipercalcemia. Pueden actuar también como antineoplásicos al inhibir la activación de proteínas vinculadas al cáncer. En los últimos años se ha incrementado su uso para la prevención de osteoporosis posmenopáusicas, gracias a que favorece el incremento en la densidad mineral ósea, lo que ha permitido la disminución de fracturas.AbstractBisphosphonates are drugs used in the treatment of primary and secondary bone ...
Subjects
free text keywords: Bisfosfonatos, Osteonecrosis maxilar, Gynecology and obstetrics, RG1-991, Bisphosphonates, Osteonecrosis of the jaw, medicine.disease, medicine, Gynecology, medicine.medical_specialty, Dentistry, business.industry, business
24 references, page 1 of 2

1. Reid IR. Osteonecrosis of the jaw - Who gets it, and why? Bone. 2009;44:4-10.

2. Aragon-Ching JB, Ning YM, Chen CC. Higher incidence of osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest. 2009;27:221-6.

3. Hellstein JE, Marek CL. Bisphosphonate osteochemonecrosis (bisphossy jaw): Is this phossy jaw of the 21st century? J Oral Maxillofac Surg. 2005;63:682-9.

4. Wang J, Goodger NM, Progrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg. 2003;61:1104-7.

5. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws. A growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-7.

6. Ruggiero S, Mehrotra B, Rosenberg T, Engroff S. Osteonecrosis of the jaws associated with the use of bisphosphonates. A review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-33.

7. Carranza S. Osteonecrosis mandibular asociada a bifosfonatos. Ginecol Obstet Mex. 2007;75:655-60.

8. Marx RE. Oral and intravenous bisphosphonate-induced osteonecrosis of de jaws, history, etiology, prevention, and treatment. Chicago: Quintessence Publishing Co. Inc., 2007. p. 1-96.

9. Fleish H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19:80-100.

10. Rang C. Farmacología. 5.ª ed. Madrid: Elsevier; 2004.

11. Mycek M. Farmacología. 2.ª ed. México: McGraw Hill; 2004.

12. Capalbo S, Delia M, Diomede D, Dargenio M, Chiefa A, Favia G, et al. Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients. Int J Hematol. 2006;83:439-42.

13. Gutta R, Louis PJ. Bisphosphonates and osteonecrosis of the jaws: science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:186-93. [OpenAIRE]

14. Herbozo PJ, Briones DL, Ferres AJ, Torrealba RL. Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:1650-4.

15. Woo SB, Hellstein JW, Kalmar J. Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753-61. [OpenAIRE]

24 references, page 1 of 2
Any information missing or wrong?Report an Issue